These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8493420)

  • 21. Data monitoring committees and capturing relevant information of high quality.
    Fleming TR
    Stat Med; 1993 Mar; 12(5-6):565-70; discussion 571-3. PubMed ID: 8493432
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Data and safety monitoring board issues raised in the VA Status Epilepticus Study.
    Collins JF
    Control Clin Trials; 2003 Feb; 24(1):71-7. PubMed ID: 12559644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Securely sharing DSMB reports to speed decision making from multiple, concurrent, independent studies of similar treatments in COVID-19.
    Dilts NA; Harrell FE; Lindsell CJ; Nwosu S; Stewart TG; Shotwell MS; Pulley JM; Edwards TL; Serdoz ES; Benhoff K; Bernard GR
    J Clin Transl Sci; 2022; 6(1):e49. PubMed ID: 35656334
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Data monitoring committees for Southwest Oncology Group clinical trials.
    Green S; Crowley J
    Stat Med; 1993 Mar; 12(5-6):451-5. PubMed ID: 8493423
    [TBL] [Abstract][Full Text] [Related]  

  • 25. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Institutionally chartered Data and Safety Monitoring Boards: structured approaches to assuring participant safety in clinical research.
    Holbein B; Rape MT; Hammack BN; Melvin A; Reider C; Knox TA
    J Investig Med; 2021 Jun; 69(5):1050-1055. PubMed ID: 34074706
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Data and safety monitoring boards: some enduring questions.
    Kowalski CJ; Hewett JL
    J Law Med Ethics; 2009; 37(3):496-506, 396-7. PubMed ID: 19723260
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Insights from monitoring the CPCRA didanosine/zalcitabine trial. Terry Beirn Community Programs for Clinical Research on AIDS.
    Fleming TR; Neaton JD; Goldman A; DeMets DL; Launer C; Korvick J; Abrams D
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 2():S9-18. PubMed ID: 7552519
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An analysis of protocols and publications suggested that most discontinuations of clinical trials were not based on preplanned interim analyses or stopping rules.
    Stegert M; Kasenda B; von Elm E; You JJ; Blümle A; Tomonaga Y; Saccilotto R; Amstutz A; Bengough T; Briel M;
    J Clin Epidemiol; 2016 Jan; 69():152-60. PubMed ID: 26361993
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ethical issues during the conduct of clinical trials.
    Silverman H
    Proc Am Thorac Soc; 2007 May; 4(2):180-4; discussion 184. PubMed ID: 17494728
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Roaming through the methodology. XIV. The premature ending of a randomized trial].
    Vandenbroucke JP
    Ned Tijdschr Geneeskd; 1999 Jun; 143(25):1305-8. PubMed ID: 10416484
    [TBL] [Abstract][Full Text] [Related]  

  • 32. How to construct an optimal interim report: What the data monitoring committee does and doesn't need to know.
    Neaton JD; Grund B; Wentworth D
    Clin Trials; 2018 Aug; 15(4):359-365. PubMed ID: 29552920
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Data safety and monitoring boards for African clinical trials.
    Lang T; Chilengi R; Noor RA; Ogutu B; Todd JE; Kilama WL; Targett GA
    Trans R Soc Trop Med Hyg; 2008 Dec; 102(12):1189-94. PubMed ID: 18644610
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Report of the Institute of Medicine Committee on the Efficacy and Safety of Halcion.
    Bunney WE; Azarnoff DL; Brown BW; Cancro R; Gibbons RD; Gillin JC; Hullett S; Killam KF; Kupfer DJ; Krystal JH; Stolley PD; French GS; Pope AM
    Arch Gen Psychiatry; 1999 Apr; 56(4):349-52. PubMed ID: 10197830
    [No Abstract]   [Full Text] [Related]  

  • 35. What information should a sponsor of a randomized trial receive during its conduct?
    Anand SS; Wittes J; Yusuf S
    Clin Trials; 2011 Dec; 8(6):716-9. PubMed ID: 22024103
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inefficacy interim monitoring procedures in randomized clinical trials: the need to report.
    Korn EL; Freidlin B
    Am J Bioeth; 2011 Mar; 11(3):2-10. PubMed ID: 21400374
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of data and safety monitoring boards in implementation trials: When are they justified?
    Fiscella K; Sanders M; Holder T; Carroll JK; Luque A; Cassells A; Johnson BA; Williams SK; Tobin JN
    J Clin Transl Sci; 2020 Mar; 4(3):229-232. PubMed ID: 32695494
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stopping rules, interim analyses and data monitoring committees.
    Ashby D; Machin D
    Br J Cancer; 1993 Dec; 68(6):1047-50. PubMed ID: 8260354
    [No Abstract]   [Full Text] [Related]  

  • 39. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
    Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
    Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Data monitoring committees for multicenter clinical trials sponsored by the National Institutes of Health. I. Roles and membership of data monitoring committees for trials sponsored by the National Eye Institute.
    Hawkins BS
    Control Clin Trials; 1991 Jun; 12(3):424-37. PubMed ID: 1651212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.